Introduction
Myocardial infarction mortality has, for a number of reasons, decreased markedly during recent decades. (1) In spite of improvements, the incidence of acute MI has remained high and cardiovascular disease is still the leading cause of death, afflicting almost 50 % of both men and women. Coronary heart disease accounts for most of the cardiovascular events, and MI is the single most important contributor to mortality and morbidity.
Historically, fewer women than men have been included in studies on coronary heart disease (CHD). Whether this is caused by lower incidence in women or actual exclusion of women from the trials have been debated. (2, 3) The consequence is that the evidence base for several treatments is less firm for women than for men.
Gender differences in treatment
Many early studies, (4-11) but not all, (12) indicated that women were treated less intensively in the acute phase of ACS. For example, women have less often received reperfusion therapy, early antithrombotic therapy and antiplatelet therapy at discharge.
Moreover, men have more often been referred for coronary angiography. (4, 5, (7) (8) (9) In some of the studies, after adjustment for age, comorbidity and severity of the disease, most of the differences disappeared. (9, 10, 13) There is also conflicting evidence on gender differences in evidence-based treatment at discharge. (4, 6, 8, 9, 11, (13) (14) (15) (16) During the last two decades increased attention has been paid to gender differences in treatment of ACS. However, there are major differences in baseline characteristics between a female and a male population with ACS that may affect the attending physician's choice of treatment, appropriateness of a certain treatment and maybe even the patient's preferences for a certain treatment.
Patophysiology
Pathogenesis of ACS involves two different processes. A slow atherosclerotic process, with low degree of reversibility, that lasts for decades, and a fast, dynamic and potentially reversible process characterized by plaque rupture or erosion, with subsequent thrombus formation. A plaque that has become large enough to compromise blood flow is the anatomical foundation for stable angina. An ACS, on the Endothelial erosion is more common in younger ACS patients and women. (17, 19) which may explain the more frequent angiographic lack of significant stenosis in women than men. (20-22) These observations indicate that there may be different pathophysiological mechanisms, afflicting men and women somewhat differently.
Risk Factors
The INTERHEART study, a case-control study from 52 countries all over the world, investigated the association of nine potentially modifiable risk factors for a first MI. (23, 24) The six factors positively associated with increased risk for a first MI were hyperlipidemia (ApoB/ApoA1 ratio), smoking, hypertension, diabetes, abdominal obesity and psychosocial stress. The three factors negatively associated with MI (i.e.
protected from MI) were physical activity, low risk diet (daily vegetables and fruits) and moderate alcohol consumption. The study confirmed that CHD determinants were the same in women and men, and these nine factors accounted for 90% of the population attributable risk in men and 94% in women. However, there were small differences between the genders in the strength of a certain risk factor. Hypertension, diabetes, physical inactivity and lack of alcohol intake were more strongly associated with MI in women than men. The study also indicated that the higher risk for MI in younger men (<60 years) compared to women of the same age was mainly due to difference in risk factor burden. Smoking is a strong risk factor for both genders but several studies have shown that smoking is an even more powerful risk factor in women. (37) In a recent meta-analysis of all blinded randomised clinical trials comparing clopidogrel and placebo the relative efficacy and safety of clopidogrel reducing CVD events in women and men was analysed. This analysis showed that there were no significant gender differences in treatment effect, reducing CVD events by 14%.
Although a greater number of women experienced bleeding complications there was no statistically significant difference between the genders. (38) In the TRITON trial, prasugrel was compared to clopidogrel in ACS patients (74% NSTE ACS), on top of aspirin. The combined end point death from cardiovascular causes, nonfatal MI or nonfatal stroke was reduced with prasugrel [9.9% vs. 12.1%, HR = 0.81, 95% CI (0.73-0.90)]. However the rate of major bleedings was significantly higher in patients receiving prasugrel (2.4% vs. 1.8%, p = 0.03). (39) Gender 
Non-responders to antiplatelet treatment
Substantial inter-individual variation in effect of both aspirin and clopidogrel has been observed (41, 42) and these so called "non-responders" or "low-responders" appear to be at increased risk for new ischemic events. 
Direct thrombin inhibitors
Hirudin has been extensively studied but with mixed results, including excess bleeding.
(52, 53) The synthetic hirudin analogue bivalirudin was compared to UFH/enoxaparin in ACS-patients (65% NSTE ACS) in the ACUITY trial. Bivalirudin alone was noninferior to bivalirudin+GPIIB/IIIa or UFH/LMWH+GPIIb/IIIa in the composite ischemic endpoint death/MI/unplanned revascularisation at 30 days, but with lower rate of bleeding. Subgroup analysis revealed that effect on the ischemic endpoint was restricted to patients receiving thienopyridines. Bleeding rates were lower with bivalirudin in all subgroups. (54) Although several subgroup analyses were performed, data on gender differences was not presented.
In the published 1 year follow-up non-inferiority with bivalirudin alone persisted.
Subgroup analysis according to gender showed no difference in effect. (55) Lack of difference in effect between the genders was confirmed in a separate analysis on patients that had PCI performed. (56) 
Factor Xa inhibitors
In the OASIS 5 trial, more than 20 000 patients with NSTE ACS were randomised to fondaparinux or enoxaparin for a maximum of 8 days. The composite primary efficacy outcome death, MI or refractory ischemia at 9 days was 5.7% with fondaparinux vs. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Bleeding complications
Bleeding complications are the most frequent non-ischemic complications in ACS patients. For example, the CURE trial reported significantly higher rate of major bleeding with the aspirin/clopidogrel combination compared to aspirin alone (3.7% vs. 65, 66) In two large scale meta-analyses increase in bleeding was associated with a stepwise increase in mortality. Not only mortality, but also ischemic events increased with major bleeding. (67, 68) Female sex has been an independent predictor of bleeding in several ACS trials with different anticoagulation strategies. (65, 69, 70) There are several factors that may explain worse outcome associated with major bleeding. Among them, potential confounders such as older age, comorbidity and renal failure, but also more causative factors such as hemodynamic instability and the possibility that bleeding triggers pro-thrombotic and pro-inflammatory processes. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 In patients with ACS undergoing PCI pooled results from recent trials indicated effect on mortality at 30 days (0.6% vs. 2.0%, p < 0.001) and 6 months (1.7% vs. 3.7%, p < 0.001) with beta-blocker therapy. (77) Although there is a paucity of gender specific data, there were no obvious differences in effect between the genders in one trial. (78) Beta-blockers are recommended for secondary prevention in the absence of contraindications, without difference between the genders. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Nitrates
In an early and small randomised trial a reduction in infarct size and left ventricular dysfunction associated with nitroglycerin-infusion was indicated. In the sub-group with anterior MI even reduction in mortality was noted. (79) More recent and large scale trials showed no benefit with nitroglycerin treatment. (80, 81) Nitrates are recommended and used primarily for symptom relief, without any known difference in effect between men and women.
Lipid lowering treatment
Statin therapy improves long-term outcome (82) and is recommended to be initiated early in all patients with ACS. (83-86) Men were in majority in most statin trials, and still gender-specific data are scarce, with somewhat contradictory results. There are studies reflecting secondary prevention, (87) primary prevention in high risk individuals (86) and primary prevention in individuals with low cholesterol but elevated CRP (88) with no apparent difference in effect between the genders. However, with a lower event rate in women, benefit was more uncertain. Moreover, the PROSPER trial (including 2 804 men and 3 000 women with a history of, or risk factors for, vascular disease) found a significant beneficial effect only in men. (89) ACE-inhibitor / A2-receptor blockers 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Revascularisation
Revascularisation is performed in the setting of ACS to relieve symptoms and to prevent progression to extended myocardial damage. In STEMI patients the treatment of choice is fast reperfusion therapy, preferably performed as primary PCI.
Regarding NSTEACS the issue has not been so easy to solve. Since the 90s there has been an intense debate whether an invasive approach, with routine coronary angiography, (followed by revascularisation if feasible), is superior to a more conservative approach in these patients. In patients with ongoing ischemic symptoms or hemodynamic or rhythm instability there is today a consensus that urgent catheterisation is the preferred treatment strategy. But, for the majority of patients with NSTE ACS, 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Another reason could be the observed gender difference in proportion of patients with elevated markers since benefit with an invasive strategy in, especially in women, appeared to be restricted to patients with elevated markers.
A third reason could be that there is a higher risk associated with an invasive strategy for women, especially regarding CABG. The higher event rate in women compared to men, treated with a routine invasive strategy, in the FRISC II trial seemed largely due to an increased rate of death and recurrent MI in women that had CABG surgery performed. Whether worse outcome in women with CABG is explained by difference in coronary artery size, comorbidity or yet other factors, is still not clear.
Conclusions
We have in this article tried to shed some light on the gender differences and similarities regarding treatment of patients with acute coronary syndromes. It is a fact that women have during the years been included in less numbers than men in clinical trials, whatever is the reason. For the future it is of utmost importance to integrate experimental studies with clinical research in order to be able to individualise the management of the patient disregarding gender and age. To get there it is necessary to have enough numbers of patients from both genders included in trials, to be able to draw proper conclusions. Until now 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Women have an increased bleeding tendency which has been shown in trials on fibrinolysis and invasive treatment. Either this is a dosing question or that women have a different metabolism than men is not clear.
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